la promotion 2024 des universitaires en Cardiologie. Felicitations à tous ! il nous reste à progresser vers la parité. Nous ne manquons pas de modèles féminins ⁦Eltchaninoff⁩ ⁦Martine Gilard⁩ MARIE-claudeMorice

fit for a cardiologist ! ( from NZ)
@harveywhitemd

📣REDUCE-AMI

🚨Very thought provocative
But be aware:
🔸LVEF>=50%, all revascularized, 80% ACEi/ARB
🔹High crossover
🔸Potentially underpowered
🔹No SCD info

🔜More trials needed & yet to come!
Paper🖇️tinyurl.com/mwb6rf8w
Editorial🖇️tinyurl.com/msx4wazy
NEJM Ph.Gabriel Steg

Latest evidence of utter failure of non-inferiority trials to set appropriate non-inferiority margins. Clinicians should ignore these margins & statistical claims of non-inferiority & instead think how their patients would balance benefits/harms/burdens. pubmed.ncbi.nlm.nih.gov/37421996/

🥸5 summary points from associated editorial by Ph.Gabriel Steg

👇👇👇

Original Article: Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md/4cEb6EB

Editorial: Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment nej.md/3vFF1LK

American College of Cardiology #ACC24

REDUCE AMI is another example of the effective registry randomized trial approach pioneered by our swedish colleagues. However, event rates were lower than expected and it was open label with some dosing and adherence issues, so not definitive. More trials are upcoming soon !

Editorial: Routine Beta-Blockers in Secondary Prevention — On Injured Reserve nej.md/3vQKorv

Beta blockers after #AMI with preserved LVEF have no benefit. Evidence-based de-prescription from 🇸🇪 Fantastic job by Troels Yndigegn et al

Routine Beta-Blockers in Secondary Prevention — On Injured Reserve | New England Journal of Medicine nejm.org/doi/full/10.10…

phenomenal ⁦Ludovic Tézier⁩ and Nicole Car in Simon Boccanegra ⁦Opéra de Paris⁩ #Verdi

desinformation criminelle…

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis - The Lancet Diabetes & Endocrinology thelancet.com/journals/landi…

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
📍 IPE consistently reduced MACE across a range of Lp(a) levels
Congrats Dr. Deepak L. Bhatt Ph.Gabriel Steg !!!
JACC Journals
jacc.org/doi/10.1016/j.…

Lp(a) Blood Levels and CV Risk Reduction With Icosapent Ethyl jacc.org/doi/10.1016/j.…
Dr. Deepak L. Bhatt Christie Ballantyne Eliot Brinton Dr Jean-Claude Tardif Michael Miller, MD #Lp (a) #Icosapentethyl

Faut-il associer un traitement antiagrégant plaquettaire chez les patients sous traitement anticoagulant ?
Ph.Gabriel Steg
ms.spr.ly/6012cWLgO

It is an honour to speak at NYU.
I was delighted to meet old friends and make new ones.
I tried to provide a hopeful yet balanced view of the trials testing factor XI Inhibition in cardiovascular diseases.
#ACS #AFib
#stroke #VTE

Thanks C. Michael Gibson MD and Ph.Gabriel Steg for leading this RCT. After years of focus on antiplatelet therapies, gives us a chance to assess benefit and risks of long term anticoagulant post ACS. Older data suggests importance of this approach.

this Aaron Rodgers interview confirms my view that i am best placed to comment on Football issues 😂😂😂

a very sad french story:
‘Failure at every level’: How science sleuths exposed massive ethics violations at a famed French institute | Science | AAAS science.org/content/articl…